Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Vivanza Biosciences approved the Director's Report and Secretarial Audit Report for FY 2024-25, and cleared the notice for the 43rd Annual General Meeting scheduled for September 25, 2025 to be held via video conferencing. The cut-off date for shareholders to vote electronically was set as September 19, 2025. Mr. Chintan K. Patel was appointed as Scrutinizer for the AGM and also as Secretarial Auditor for five financial years (FY 2025-26 to FY 2029-30), pending shareholder approval. Most notably, the Board approved a major alteration to the company's main object clause to diversify into agro products, solar and renewable energy, infrastructure, real estate, drones, IT, software development, data centres, and cloud services, subject to shareholder approval through a Special Resolution.
The main object clause alteration signals a significant strategic pivot — the company plans to move well beyond its biosciences identity into multiple unrelated sectors like solar energy, IT, drones, and real estate, which could reshape its business profile but also raises questions about execution focus. The AGM notice and routine approvals are standard procedural items with no immediate price impact, though the diversification plan may attract speculative interest.